Billie Walters
Acute Care · Lexington, KYNPI 1477938090
Payments from drug & device makers
Across 828 payments — averaging $23.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- AbbVie$2K
- AstraZeneca$2K
- UCB, Inc.$2K
- Livanova USA, Inc.$2K
- Biogen$1K
- plus $7K from 26 others
What the payments were for
- Consulting fees$1,4407%
- Travel & lodging$1,7549%
- Food & beverage$15,91480%
- Education$7114%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 27 | $2,882 |
| AbbVie | 174 | $2,398 |
| AstraZeneca(2 entities) | 48 | $2,033 |
| UCB, Inc. | 90 | $1,945 |
| Livanova USA, Inc. | 10 | $1,739 |
| Biogen | 71 | $1,443 |
| Novartis | 85 | $1,335 |
| Pfizer | 90 | $936 |
| Teva Pharmaceuticals USA, Inc. | 35 | $676 |
| Argenx US, Inc. | 32 | $634 |
| TG Therapeutics, Inc. | 19 | $484 |
| Neurocrine Biosciences, Inc. | 20 | $462 |
| Genentech USA, Inc. | 23 | $455 |
| EMD Serono, Inc. | 10 | $312 |
| Lilly USA, LLC | 16 | $280 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $227 |
| Bristol Myers Squibb | 12 | $214 |
| Sanofi | 7 | $205 |
| Johnson & Johnson | 7 | $202 |
| SK Life Science, Inc. | 8 | $178 |
| Jazz Pharmaceuticals Inc. | 8 | $166 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $138 |
| Kyowa Kirin, Inc. | 1 | $135 |
| Lundbeck LLC | 5 | $89 |
| Otsuka America Pharmaceutical, Inc. | 4 | $64 |
| Supernus Pharmaceuticals, Inc. | 2 | $40 |
| Avanir Pharmaceuticals, Inc. | 2 | $32 |
| Corium, LLC | 1 | $30 |
| Grifols USA, LLC | 1 | $30 |
| Eisai Inc. | 1 | $23 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| Neurelis, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,819 in reported general payments places this provider in the 95th percentile of 319 acute care providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 27 | $229,259 |
| Nurtec OdtRimegepant Sulfate | 51 | $96,512 |
| QuliptaAtogepant | 62 | $68,176 |
| UbrelvyUbrogepant | 39 | $43,388 |
| Emgality PenGalcanezumab-Gnlm | 56 | $40,654 |
| Aimovig AutoinjectorErenumab-Aooe | 41 | $30,006 |
| BotoxOnabotulinumtoxina | 17 | $20,832 |
| Dalfampridine ErDalfampridine | 24 | $6,586 |
| Donepezil Hcl | 395 | $3,096 |
| Memantine Hcl | 223 | $3,088 |
| TecfideraDimethyl Fumarate | 12 | $2,797 |
| Gabapentin | 199 | $2,664 |
| Oxcarbazepine | 58 | $2,248 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 26 | $1,921 |
| Propranolol Hcl | 110 | $1,300 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy, Botox | $2,398 | $132,396118 claims |
| PfizerNurtec Odt | $936 | $96,51251 claims |
| BiogenTecfidera | $1,443 | $2,79712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 319 acute care providers in Kentucky.
Other acute care in Lexington
- Audra MarcumLexington$14K
- Holly ChitwoodLexington$10K
- Chadwick HuntLexington$6K
- Nicole ClevingerLexington$5K
- Sara StarksLexington$4K
- Autumn WestmorelandLexington$4K
- Charles BeachLexington$4K
- Lauren DavisLexington$4K
- Alicia ReamsLexington$4K
- Kyle BloomfieldLexington$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.